Pseudo-ginseng active composition, meal replacement powder and application of pseudo-ginseng active composition and meal replacement powder in improving intestinal microecology, losing weight, reducing blood sugar and reducing lipid

Abstract

The invention discloses a pseudo-ginseng active composition, meal replacement powder and application of the pseudo-ginseng active composition and the meal replacement powder in improving intestinal microecology, losing weight, reducing blood sugar and reducing lipid. The panax notoginseng active composition comprises 15 active components and not less than 1 billion / g of bacillus inulin viable bacteria powder, the inhibition rate on alpha-glucosidase is not less than 51.49%, and the OARC value is not less than 32.60 micromoles TE / mL. The meal replacement powder prepared from the pseudo-ginseng active composition not only has the effects of reducing blood sugar and blood fat and losing weight on diabetic model mice, but also has small damage to mouse visceral organs, and the analysis of mouse intestinal flora finds that the meal replacement powder provided by the embodiment of the invention has the effect of improving the abundance of mouse intestinal thick-wall mycophylum; the intestinal microecology of the mouse can be favorably converted to the probiotic direction.

Description

Technical Field

[0001] The present application relates to the technical field of Panax notoginseng, and in particular to a Panax notoginseng active composition, a meal replacement powder and its application in improving intestinal microecology and reducing weight, blood sugar and lipids. Background Art

[0002] Panax notoginseng is the dried rhizome of Polygouum amplexic-aide D.Donvar.siueu.se, a plant of the Polygouum genus of the Polygouaceae family. It is a commonly used medicinal material for the Miao and Tujia ethnic groups. According to traditional Chinese medicine theory, it tastes astringent and slightly bitter, and has the effects of promoting blood circulation and relaxing muscles, dispelling addiction and relieving pain, antibacterial and anti-inflammatory, and hemostasis and tissue regeneration. It is clinically used to treat diseases such as traumatic injuries and gastroenteritis. Modern pharmacological research results have shown that Panax notoginseng has antifungal, antioxidant and adjuvant treatment effects on atherosclerosis. In recent years, literature reports have shown that the active ingredients of Panax notoginseng have also played an important role in tumor prevention and treatment. However, at present, there are still few studies on the bioactive ingredients and pharmacological effects of Panax notoginseng. It is of great practical significance to fully explore the active ingredients of Panax notoginseng and further explore its wider application value. Summary of the invention

[0003] In view of this, the purpose of the present application is to develop a Panax notoginseng active composition and its related products and applications that can have broader application prospects.

[0004] In the first aspect, the embodiments of the present application disclose a Panax notoginseng active composition, including resveratrol, phloridzin, quercetin, 6-methoxy-7-hydroxycoumarin, catechin, candelilla resin phenol, methyl protocatechuate, methyl gallate, n-butyl gallate, 6-O-(E)-caffeoyl glucoside, carotene, benzoyl β-D-pyranoglucoside, 2,8-triol-1-O-β-D-pyranoglucoside, quercetin-3-O-α-D-furanosyl arabinoside and ferulic acid, and not less than 100 million / g of live bacterial powder of Lactobacillus inulinus.

[0005] In the examples of the present application, the Panax notoginseng active composition comprises, by weight per thousand, 14.20-16.24 wt‰ resveratrol, 16.48-18.16 wt‰ phlorizin, 12.50-13.12 wt‰ quercetin, 4.69-4.95 wt‰ 6-methoxy-7-hydroxycoumarin, 6.498-6.622 wt‰ catechins, 2.088-2.172 wt‰ southern candelilla resin phenol, 1.053-1.127 wt‰ protocatechuic acid methyl ester, 0.794-0.846 wt‰ methyl gallate, 0.612-0.6 48wt‰ gallic acid n-butyl ester, 0.415-0.445wt‰ 6-O-(E)-caffeoyl glucoside, 1.732-1.848wt‰ carotene, 12.19-14.31wt‰ benzoyl β-D-pyranoglucoside, 3.68-4.56wt% 2,8-triol-1-O-β-D-pyranoglucoside, 5.153-5.327wt‰ quercetin-3-O-α-D-furanosyl arabinoside and 9.23-10.87wt‰ ferulic acid, and not less than 100 million / g of inulin spore lactobacillus live bacterial powder.

[0006] In the examples of the present application, the Panax notoginseng active composition comprises, by weight per thousand, 11.93-14.61 wt‰ resveratrol, 17.41-20.69 wt‰ phlorizin, 9.18-11.08 wt‰ quercetin, 1.87-2.75 wt‰ 6-methoxy-7-hydroxycoumarin, 4.108-5.212 wt‰ catechins, 1.732-1.788 wt‰ southern candelilla resin phenol, 0.745-0.775 wt‰ protocatechuic acid methyl ester, 0.317-0.363 wt‰ methyl gallate, 0.449-0.49 1wt‰ gallic acid n-butyl ester, 0.546-0.574wt‰ 6-O-(E)-caffeoyl glucoside, 1.426-1.534wt‰ carotene, 16.93-19.39wt‰ benzoyl β-D-pyranoglucoside, 2.89-3.61wt‰ 2,8-triol-1-O-β-D-pyranoglucoside, 2.732-2.848wt‰ quercetin-3-O-α-D-arabinofuranoside and 13.56-17.14wt‰ ferulic acid, and not less than 100 million / g of live bacterial powder of Lactobacillus inulinus.

[0007] In the examples of the present application, the Panax notoginseng active composition comprises, by weight per thousand, 14.02-16.26 wt‰ resveratrol, 12.21-14.69 wt‰ phlorizin, 10.19-11.97 wt‰ quercetin, 4.42-4.94 wt‰ 6-methoxy-7-hydroxycoumarin, 7.744-7.896 wt‰ catechins, 2.799-2.861 wt‰ southern candelilla resin phenol, 1.189-1.311 wt‰ protocatechuic acid methyl ester, 0.817-1.003 wt‰ methyl gallate, 0.738-0.7 82wt‰ gallic acid n-butyl ester, 0.519-0.5761wt‰ 6-O-(E)-caffeoyl glucoside, 1.448-1.612wt‰ carotene, 9.52-11.94wt‰ benzoyl β-D-pyranoglucoside, 4.07-4.77wt‰ 2,8-triol-1-O-β-D-pyranoglucoside, 5.053-5.187wt‰ quercetin-3-O-α-D-furanosyl arabinoside and 9.11-10.37wt‰ ferulic acid, and not less than 100 million / g of inulin spore lactobacillus live bacterial powder.

[0008] In the examples of the present application, the inhibitory rate of the Panax notoginseng active composition on α-glucosidase is not less than 51.49%, and the OARC value is not less than 32.60 μmol TE / mL.

[0009] In a second aspect, the embodiments of the present application disclose a meal replacement powder for weight loss, blood sugar and lipid reduction, comprising 0.0001 to 10 parts of the Panax notoginseng active composition powder described in the first aspect, 50 to 80 parts of soluble dietary fiber and other food-friendly excipients.

[0010] In a third aspect, the present application discloses a method for preparing the notoginseng active composition described in the first aspect, comprising the following steps:

[0011] preparing a working seed solution containing live bacteria of Sporolactobacillus inulinus;

[0012] preparing a seed solution, wherein the seed solution is inoculated into a seed culture medium by the working seed solution, and cultured at 37° C. for 18 hours to obtain the seed solution;

[0013] preparing a fermentation broth, wherein the fermentation broth is obtained by inoculating the seed liquid into a fermentation medium for cultivation; and

[0014] The fermentation liquid is concentrated and dried to obtain the Panax notoginseng active composition;

[0015] The seed culture medium contains 2-5 g / L Jerusalem artichoke powder, 6-20 g / L Panax notoginseng powder, 0.1-7 g / L corn flour and 0.1-8 g / L buckwheat flour; the fermentation culture medium contains 3-6 g / L Jerusalem artichoke powder, 8-20 g / L Panax notoginseng powder, 0.1-8 g / L corn flour and 0.1-8 g / L buckwheat flour.

[0016] In an embodiment of the present application, the working seed solution is prepared by inoculating activated Lactobacillus inulinus onto an acclimation medium for acclimation culture, wherein the acclimation medium contains 8-18.0 g / L Jerusalem artichoke whole powder and 2.0-12 g / L Panax notoginseng powder.

[0017] In an embodiment of the present application, the acclimation culture includes acclimation culture carried out in a first acclimation medium, a second acclimation medium and a third acclimation medium, respectively. The first acclimation medium contains 18.0 g / L Jerusalem artichoke whole powder and 2.0 g / L Panax notoginseng powder, the second acclimation medium contains 10.0 g / L Jerusalem artichoke whole powder and 10.0 g / L Panax notoginseng powder, and the third acclimation medium contains 8.0 g / L Jerusalem artichoke whole powder and 12.0 g / L Panax notoginseng powder.

[0018] In a fourth aspect, the embodiments of the present application disclose the use of the Panax notoginseng active composition described in the first aspect, or the Panax notoginseng active composition prepared by the preparation method described in the second aspect, in the preparation of health products related to weight loss, blood sugar and lipid reduction.

[0019] Compared with the prior art, this application has at least the following beneficial effects:

[0020] The present application utilizes inulin spore lactobacillus to ferment Panax notoginseng powder to prepare a freeze-dried powder containing live bacteria of inulin spore lactobacillus and Panax notoginseng related blood sugar and lipid-lowering active ingredients. After analyzing the active ingredients in the freeze-dried powder, it was found that the fermentation method of the present application can not only fully increase and enrich the content of Panax notoginseng related blood sugar and lipid-lowering active ingredients, but also comprehensively enrich these active ingredients, providing an application prospect for it as a health product that can reduce blood sugar and lipids and effectively lose weight.

[0021] Therefore, the embodiment of the present application further uses the freeze-dried powder to prepare a meal replacement powder, and in vivo experiments confirm the blood sugar and lipid lowering and weight loss effects of the meal replacement powder on KK / Upj-Ay / J diabetic model mice, with little damage to the mouse organs and no obvious toxic side effects. The intestinal flora analysis of mice also found that the meal replacement powder provided in the embodiment of the present application has the effect of increasing the abundance of Firmicutes in the mouse intestine, thereby transforming the mouse intestinal microecology towards a probiotic direction. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 The pH value changes during the fermentation process of Examples 1 to 3 and Comparative Examples 1 to 6 of the present application.

[0023] Figure 2 This is a staining image of the adipocyte sections of normal mice provided for the in vivo experiment of this application.

[0024] Figure 3 This is a staining image of the adipocyte sections of the model group mice provided for the in vivo experiment of this application.

[0025] Figure 4 Staining diagram of fat cell sections of mice in the intervention group (Example 1) provided for the in vivo experiment of this application.

[0026] Figure 5 This is a staining diagram of mouse adipocyte sections from the positive control group (Example 1) provided for the in vivo experiment of this application. DETAILED DESCRIPTION

[0027] In order to make the purpose, technical solution and advantages of the present application more clear, the present application is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described here are only used to explain the present application and are not used to limit the present application.

[0028] Probiotic fermentation

[0029] 1. Materials and Methods

[0030] 1. Biomaterials

[0031] Panax notoginseng, dried goods, ground into powder, brings happiness to every family in Wenshan.

[0032] Auxiliary materials: Buckwheat flour was purchased from Xinghua Yufeng Food Co., Ltd., and corn flour was purchased from Xi'an Clover Biotechnology Co., Ltd.

[0033] Sporolactobacillus inulinus (SI for short), catalog number B81253, was purchased from Mingzhou Biotechnology.

[0034] 2. Preparation of working seed solution

[0035] The lyophilized powder of Sporobacillus inulinus was activated using glucose yeast extract peptone (GYP) medium. The first activation of the lyophilized powder should be completely used up. 0.5 mL of the above culture solution was used for solution and inoculated on a GYP solid plate. After culturing at 33° C. for 15 to 18 hours, a single colony was picked and inoculated on an acclimation medium for acclimation culture.

[0036] In the implementation process of the specific embodiment 1, the acclimation culture includes the step of inoculating the activated SI colony into the first acclimation culture medium for acclimation; a specific embodiment of the formula of the first acclimation culture medium is: 10.0g of casein digest, 15.0g of beef extract powder, 2.0g of triammonium citrate, 5.0g of sodium acetate, 0.05g of manganese sulfate, 0.2g of magnesium sulfate, 2.0g of dipotassium hydrogen phosphate, 18.0g of Jerusalem artichoke powder, 2.0g of Panax notoginseng powder, 1. 5g α-amylase (Xiasheng FDY-2801), 1.2g β-amylase (Xiasheng FDG-2258), 1mL Tween, add distilled water to 1000mL, boil to dissolve, adjust pH to 7.0 (20-25℃), sterilize at 121℃ for 20min, cool and package, inoculate the activated SI single colony into the acclimation medium at a rate of 12wt%, and culture at 36℃ for 15-18h to obtain the working seed solution.

[0037] During the implementation of the specific embodiment 2, the step of acclimation and cultivation includes the steps of transferring the active SI colonies to the first, second, and third acclimation culture media for cultivation in sequence; the second acclimation culture medium contains 10.0 g / L Jerusalem artichoke whole powder and 10.0 g / L Panax notoginseng powder, and the other ingredients are the same as the first acclimation culture medium, the inoculation amount is 10 wt%, and the culture is carried out at 38°C for 15 to 18 hours; and the colonies are transferred to the third acclimation culture medium again, the third acclimation culture medium contains 8.0 g / L Jerusalem artichoke whole powder and 12.0 g / L Panax notoginseng powder, and the other ingredients are the same as the first acclimation culture medium, the inoculation amount is 10 wt%, and the working seed solution can be obtained after culturing at 38°C for 15 to 18 hours.

[0038] In the implementation process of specific comparative example 1, the relevant acclimatization and culture steps were not performed, but the activated SI colony was directly inoculated into the working seed culture medium. The formula of a specific working seed culture medium used in comparative example 1 included 20 g / L glucose, 10 g / L peptone, 10 g / L beef extract, 5 g / L yeast extract, 2 g / L diammonium hydrogen citrate, 5 g / L sodium acetate, 2 g / L dipotassium hydrogen phosphate, 0.25 g / L manganese sulfate, 0.5 g / L magnesium sulfate, 1 mL Tween 80, pH 6.4, sterilized at 121 ° C for 15 min, and cultured at 40 ° C for 16 h to make a working seed bacterial solution with an OD600 value of more than 0.2.

[0039] 3. Preparation of seed solution and fermentation solution

[0040] The working seed solutions prepared in the above-mentioned Examples 1, 2 and 1, respectively, were inoculated into the seed culture medium and cultured at 37° C. for 18 h. A specific seed culture medium formula comprises: 25.0 g beef extract powder, 3.0 g Jerusalem artichoke powder, 12.0 g Panax notoginseng powder, 5.0 g corn flour, 7.0 g buckwheat flour, 2.0 g triammonium citrate, 5.0 g sodium acetate, 0.05 g manganese sulfate, 0.2 g magnesium sulfate, 2.0 g dipotassium hydrogen phosphate, 1 mL Tween, add distilled water to 1000 mL, boil and dissolve, adjust the pH to 7.0 (20-25° C.), sterilize at 121° C. for 20 min, cool and package, and then add the working seed solution to the seed culture medium at an inoculation amount of 12 wt %, and culture at 36° C. for 15-18 h to obtain the seed solution.

[0041] The seed liquid is inoculated into the fermentation medium according to the inoculation amount of 8wt% to obtain the fermentation liquid. A specific formula of the fermentation medium includes: 20.0g beef paste powder, 5.0g Jerusalem artichoke powder, 15.0g Panax notoginseng powder, 8.0g corn flour, 10.0g buckwheat flour, 2.0g triammonium citrate, 5.0g sodium acetate, 0.05g manganese sulfate, 0.2g magnesium sulfate, 2.0g potassium hydrogen phosphate, 1mL Tween, add distilled water to 1000mL, boil and dissolve, sterilize at 121℃ for 20min, and put into the fermentation tank after cooling. Sterile air is not passed in the early stage of fermentation, 40℃, as the cell concentration (OD600 value increases), the redox potential and carbon dioxide change. After 4h of cultivation, it is transferred to the microaerobic cultivation stage, and the sterile air flow is controlled according to the changes in the redox potential and carbon dioxide. During the fermentation for 4 to 30 hours, the redox potential is controlled at -150mV to -180mV, and the carbon dioxide content of the tail gas is controlled at 15% to 20%. After 30 hours of fermentation, sterile air is no longer passed, and the fermentation ends after 56 hours.

[0042] The implementation process of Example 3 is as follows: the working seed solution used is the same as the working seed solution prepared in Example 1, but the formulas of the seed culture medium and the fermentation culture medium in the experiment are: 25.0g beef paste powder, 3.0g Jerusalem artichoke whole powder, 12.0g Panax notoginseng powder, 5.0g corn flour, 7.0g buckwheat flour, 2.0g triammonium citrate, 5.0g sodium acetate, 0.05g manganese sulfate, 0.2g magnesium sulfate, 2.0g dipotassium hydrogen phosphate, 1mL Tween, and distilled water to 1000mL.

[0043] The implementation process of Comparative Example 2 is as follows: the working seed solution used is the same as the working seed solution prepared in Example 1, but the formulas of the seed culture medium and the fermentation culture medium in the experiment are: 20g / L glucose, 10g / L peptone, 10g / L beef extract, 5g / L yeast extract, 2g / L diammonium hydrogen citrate, 5g / L sodium acetate, 2g / L dipotassium hydrogen phosphate, 0.25g / L manganese sulfate, 0.5g / L magnesium sulfate, 1mL Tween 80, pH7.0, sterilized at 121°C for 15min, and cultured at 40°C for 56h; thereby, the fermentation liquid is obtained by fermentation.

[0044] The implementation process of Comparative Example 3 is as follows: the working seed solution used is the same as the working seed solution prepared in Example 2, but the formulas of the seed culture medium and the fermentation culture medium used are: 20 g / L glucose, 10 g / L peptone, 10 g / L beef extract, 5 g / L yeast extract, 2 g / L diammonium hydrogen citrate, 5 g / L sodium acetate, 2 g / L dipotassium hydrogen phosphate, 0.25 g / L manganese sulfate, 0.5 g / L magnesium sulfate, 1 mL Tween 80, pH 7.0, sterilized at 121 ° C for 15 min, and cultured at 40 ° C for 56 h; thereby, the fermentation liquid is obtained by fermentation.

[0045] The implementation process of Comparative Example 4 is as follows: the working seed solution used is the same as the working seed solution prepared in Comparative Example 1, but the formulas of the seed culture medium and the fermentation culture medium in the experiment are: 20g / L glucose, 10g / L peptone, 10g / L beef extract, 5g / L yeast extract, 2g / L diammonium hydrogen citrate, 5g / L sodium acetate, 2g / L dipotassium hydrogen phosphate, 0.25g / L manganese sulfate, 0.5g / L magnesium sulfate, 1mL Tween 80, pH7.0, sterilized at 121°C for 15min, and cultured at 40°C for 56h; thereby, the fermentation liquid is obtained by fermentation.

[0046] The implementation process of Comparative Example 5 is as follows: the working seed solution used is the same as the working seed solution prepared in Example 1, but the formulas of the seed culture medium and the fermentation culture medium in the experiment are: 25.0g beef paste powder, 3.0g Jerusalem artichoke whole powder, 20.0g glucose powder, 2.0g triammonium citrate, 5.0g sodium acetate, 0.05g manganese sulfate, 0.2g magnesium sulfate, 2.0g dipotassium hydrogen phosphate, 1mL Tween, add distilled water to 1000mL, adjust pH7.0, sterilize at 121°C for 15min, and culture at 40°C for 16h; thereby, the fermentation liquid is obtained by fermentation.

[0047] The implementation process of Comparative Example 6 is as follows: the working seed solution used is the same as the working seed solution prepared in Example 1, but the formulas of the seed culture medium and the fermentation culture medium in the experiment are: 25.0g beef paste powder, 5.0g corn flour, 7.0g buckwheat flour, 2.0g triammonium citrate, 5.0g sodium acetate, 0.05g manganese sulfate, 0.2g magnesium sulfate, 2.0g dipotassium hydrogen phosphate, 1mL Tween, add distilled water to 1000mL, adjust pH7.0, sterilize at 121°C for 15min, and culture at 40°C for 16h; thereby, the fermentation liquid is obtained by fermentation.

[0048] 4. Determination of relevant indicators

[0049] The fermentation broths provided in Examples 1 to 3 and Comparative Examples 1 to 6 were collected and the following related indexes were measured.

[0050] Determination of the number of live lactic acid bacteria and yeasts: Use the dilution pour plate method, referring to the method for determining the total number of yeast and lactic acid bacteria colonies in GB 4789-2010.

[0051] pH determination: The pH of the fermented broth was directly measured using a PB-10 pH meter.

[0052] Determination of antioxidant capacity: The ORAC of the fermentation broth prepared in the above-mentioned examples and comparative examples was determined by the oxygen radical absorbance capacity (ORAC) method, and the results were expressed in μmol TE / mL (μmol TE / g).

[0053] The determination method is as follows: 20 μL of diluted sample solution and Trolox standard solution (Wajun Pharmaceutical Co., Ltd., Japan) are added to the microwells of a 96-well plate, and then 80 μL of 1.25 μmol / L fluorescein sodium solution (prepared with 75 mmol / L phosphate buffer at pH 7.4) is added and mixed evenly, and the reaction is carried out at 37°C in the dark for 10 minutes; then 100 μL of 140 mmol / L free radical generator AAPH (prepared with 75 mmol / L phosphate buffer at pH 7.4) is added, and after mixing, the microwell plate is placed in an ELISA reader, and a multi-point cycle determination is performed at 37°C with an excitation wavelength of 485 nm and an emission wavelength of 520 nm. The fluorescence intensity of each microwell is measured every 2 minutes, and the determination time is generally set until the fluorescence decays to the baseline. The experiment is divided into negative control group 1, negative control group 2 and experimental group. No free radical generator AAPH is added to the wells of the negative control group 1. No Trolox standard solution was added to the wells of the negative control group 2. The antioxidant capacity of the sample is directly related to the delayed area of ​​the fluorescence decay curve under the action of free radicals (Net AUC). The fluorescence intensity data of each microwell reaction obtained in the experiment was output by the software and statistically processed by SPSS. The absolute fluorescence intensity data of each well at different time points were compared with the fluorescence intensity of the negative control group 1 and converted into relative fluorescence intensity f. The area under the quenching curve (AUC) was calculated using the approximate integration method based on the relative fluorescence intensity. The OARC value = [(AUC 样品 -AUC 阴性对照组2 ) / (AUC 标准品 -AUC 阴性对照组2 )]×(Trolox standard solution volume / sample volume).

[0054] Determination of α-glucosidase inhibition rate: Take 50 μL of sample (fermentation broth provided in each embodiment and comparative example) in a 96-well sterile cell plate, and add 0.1 M phosphate buffer at pH 6.9 containing 100 μL 1u / mL α-glucosidase (G5003-100UN), react at 25 ° C for 10 minutes, and then continue to add 50 μL of 0.1 M phosphate buffer at pH 6.9 containing 1.5 mM nitrobenzene-α-D-pyranoglucoside. After mixing, immediately use a microplate reader to measure the absorbance at 405 nm. The well plate with 50 μL of 0.1 M phosphate buffer at pH 6.9 is used as a blank control, and the α-glucosidase inhibition rate (%) is calculated according to the formula = (1-A sample / A blank) × 100%.

[0055] Determination of monosaccharide content: After adding 2 volumes of anhydrous ethanol to the sample to be tested (the fermentation broth provided in each embodiment and comparative example) and ultrasonically treating for 30 minutes, the sample was centrifuged at 8000rpm for 10 minutes, filtered with a 0.22μm filter membrane, and then used for HPLC analysis of the monosaccharide content. The chromatographic conditions were: a high performance liquid chromatography column for carbohydrate analysis (4.6mm×250mm, 5μm, Cosmosil Sugar-D), a column temperature of 30°C, an evaporative light detector for detection, and an ELSD drift tube temperature of 40°C; the mobile phase was 75% acetonitrile, the flow rate was 1mL / min, and the injection volume was 10μL; the monosaccharide content was quantitatively analyzed using the external standard method.

[0056] Determination of organic acid content: extract the sample with a certain amount of metaphosphoric acid solution, ultrasonically treat for 30 minutes, centrifuge at 8000rpm for 10 minutes, take the supernatant, filter with 0.22μm filter membrane, and use for HPLC analysis. The chromatographic conditions are: Aquasil C18 column (4.6mm×250mm, 5μm); mobile phase is 0.1% ammonium dihydrogen phosphate at pH2.7, isocratic elution for 15 minutes, flow rate is 1mL / min, injection volume is 20μL, detection wavelength is 210nm. The organic acid content is determined by external standard method.

[0057] 5. Data processing

[0058] All test data were expressed as mean and standard deviation. SPSS13.0 software was used to process the data, and multiple comparisons and significant differences were marked for each column of data.

[0059] 2. Results

[0060] Table 1

[0061]

[0062] As shown in Table 1, the number of viable Lactobacillus inulinus in the fermentation broth provided by Examples 1 to 3 is significantly higher than that of Comparative Examples 1 to 6 (except Comparative Example 4), which indicates that the fermentation method provided by the embodiments of the present application can provide a fermentation broth with a higher number of viable bacteria. In Table 1, "-" means that no viable bacteria were detected. Figure 1 It can be seen that from the fermentation process of the 0th to 56th hour, in the fermentation process of each embodiment 1 to 3, the fermentation pH value rapidly decreases during the 0th to 12th hour, and the pH value of the fermentation liquid is relatively stable after 36 hours of fermentation; and except for comparative example 4, the pH value of the fermentation liquid of the other comparative examples gradually decreases during the fermentation process, and the pH value of the fermentation liquid after the fermentation is completed is lower than that of the embodiment. In addition, it can be seen from Table 1 that the organic acid content in the fermentation liquid obtained by the final fermentation of embodiments 1 to 3 is low; while the organic acid content in the fermentation liquid obtained by comparative examples 1 to 3 is high, acetic acid and citric acid are not detected in the fermentation liquid provided by comparative example 4, and the organic acid content in comparative examples 5 and 6 is equivalent to that of the embodiment.

[0063] Table 2

[0064]

[0065]

[0066] Table 2 lists the fructose and glucose content in each fermentation broth, as well as the OARC value and α-glucosidase inhibition rate of each fermentation broth. In Table 2, "-" indicates that it is not detected. As can be seen from the results, the fructose and glucose content in the fermentation broth provided by Examples 1 to 3 is significantly lower than that in Comparative Examples 1 to 6, and Example 3 does not even detect monosaccharide components, which indicates that the fermentation broth provided in the examples of the present application is a low-sugar content fermentation broth.

[0067] Furthermore, it can be seen from Table 2 that the OARC values ​​and α-glucosidase inhibition rates of the fermentation broths provided in Examples 1 to 3 are significantly higher than those in the comparative example, which indicates that the fermentation broth of Lactobacillus inulinus provided in the examples of the present application has excellent antioxidant and α-glucosidase inhibition functions.

[0068] Analysis of active ingredients in fermentation broth

[0069] 1. Post-treatment of fermentation liquid

[0070] (1) Extract

[0071] The fermentation broths prepared in the above Examples 1 to 3 and Comparative Examples 1 to 6 were collected, concentrated under reduced pressure at 65° C., added to 9 times the volume of 95% ethanol aqueous solution, magnetically stirred for 30 min, centrifuged at 2000 rpm for 10 min, and the supernatant was concentrated under reduced pressure to obtain a first extract.

[0072] (2) Extraction

[0073] The extract was dissolved in 90% methanol and then extracted with an equal volume of petroleum ether for 3 to 5 times, and the lower phase was taken and recovered under reduced pressure to obtain a second extract;

[0074] The second extract is extracted with isobutyl alcohol, propanol, tetrahydrofuran and acetone in sequence, and the lower layer of extract or solution after each stage of extraction is used as the extract to be extracted in the next stage.

[0075] Thus, an isobutanol extract, a propanol extract, a tetrahydrofuran extract and an acetone extract are obtained in sequence, and these extracts are respectively concentrated under reduced pressure and freeze-dried to remove the solvent therein to obtain the corresponding freeze-dried powder.

[0076] 2. Active ingredient detection of freeze-dried powder

[0077] The isobutanol extract and the propanol extract were detected by reverse liquid chromatography, with a Waters Sunfire ODS C18 column (250 mm×4.6 mm, 5 μm) as the chromatographic column, acetonitrile-water as the mobile phase, gradient elution, a flow rate of 1.0 ml / min, a variable detection wavelength (0 min, 230 nm; 10 min, 283 nm; 25 min, 203 nm), a column temperature of 30°C, and an injection volume of 10 μL.

[0078] Test sample: The lyophilized powders of the above-mentioned isobutanol extract, propanol extract, tetrahydrofuran extract and acetone extract were prepared into 1.0 mg / mL solutions using the corresponding isopropanol, propanol, tetrahydrofuran and acetone as solvents, respectively, as test samples.

[0079] Standards: The standards involved in this experiment are shown in Table 3.

[0080] Table 3 Standards

[0081]

[0082] 3. Results

[0083] Table 4

[0084]

[0085]

[0086] Table 4 lists the fermentation broth obtained by the fermentation method of Examples 1 to 3 and Comparative Examples 1 to 6, which were post-treated to obtain freeze-dried powders of isobutanol extracts, propanol extracts, tetrahydrofuran extracts and acetone extracts, respectively. After mixing these freeze-dried powders, the above-mentioned reverse phase chromatography was used to detect the weight percentage of H1 to H15 in the freeze-dried powder of the fermentation broth. "wt‰" means weight per thousand. In addition, the present application also directly uses the powder of Panax notoginseng as Comparative Example 7, and adopts the above-mentioned extract and extraction steps to obtain freeze-dried powders of isobutanol extracts, propanol extracts, tetrahydrofuran extracts and acetone extracts. After mixing these freeze-dried powders, the above-mentioned reverse phase chromatography was used to detect the weight percentage of H1 to H15 compounds in the powder of Panax notoginseng. In Table 4, the unspecified components in the H1 to H15 compounds represent that the compound was not detected.

[0087] It can be seen from Table 4 that compared with Comparative Example 7, not only are the components of H1 to H15 retained in Examples 1 to 3, but their content ratios are also increased by 3 data levels, greatly enriching the relevant active ingredients in Panax notoginseng.

[0088] In Comparative Examples 1 and 4, since the working seed solution prepared in Comparative Example 1 was used in the fermentation process, the fermentation liquids were subjected to post-processing, resulting in a large loss of Panax notoginseng-related active ingredients in the freeze-dried extract powders. In Comparative Examples 2, 3 and 6, since the culture medium formulas in the fermentation process were different, the fermentation liquids were subjected to post-processing, resulting in a large loss of Panax notoginseng-related active ingredients in the freeze-dried extract powders. The relevant Panax notoginseng active ingredients in the freeze-dried extract powder prepared in Comparative Example 5 were retained.

[0089] In vivo experiments

[0090] 1. Materials and Methods

[0091] 1. Experimental Animals

[0092] SPF grade KK / Upj-Ay / J diabetic model mice, weight 24.5±2.3g, half male and half female, fed 60 Co mouse feed 1025, Guangzhou Saibinuo Biotechnology Co., Ltd.

[0093] SPF grade C56BL / 6J mice, weighing 20.1±1.6g, half male and half female, fed normally, obtained from Beijing Huafukang Biotechnology Co., Ltd.

[0094] The experimental animals were kept in IVC cages at a temperature of 21-25°C and a humidity of 40-70%. The diabetic model mice were fed a special high-fat, high-energy feed. 60 Co mouse feed 1025, C57BL / 6J mice fed with SPF special feed, was purchased from Beijing Huafukang Biotechnology Co., Ltd.

[0095] 2. Test products

[0096] This experiment will prepare a meal replacement powder based on the above Examples 1 to 3 and Comparative Examples 1 to 7 to test its blood sugar and lipid lowering and weight loss effects on model mice. The specific preparation process can be referred to as follows:

[0097] All basic raw materials are ball-milled to a specified particle size, and after passing through a 100-mesh sieve, the soluble dietary fiber component, the freeze-dried powder provided in Examples 1 to 3 or Comparative Examples 1 to 7, and other auxiliary materials are pre-mixed in a three-dimensional mixer using a multiple dispersion process technology to obtain the meal replacement powder.

[0098] To this end, the embodiments of the present application also disclose a meal replacement powder with the functions of lowering blood sugar, lowering blood lipids and losing weight, which includes 0.0001 to 10 parts of the freeze-dried powder prepared in the above embodiments 1 to 3, 50 to 80 parts of soluble dietary fiber and other food-friendly excipients.

[0099] The lyophilized powder obtained in Examples 1 to 3 is obtained by concentrating and freeze-drying the fermentation broth obtained by fermentation in Examples 1 to 3, and a freeze-drying protective agent of not more than 6 wt % may be added during the freeze-drying process. Specifically, the freeze-drying protective agent is selected from at least one of skim milk, sucrose, trehalose, dextran and sodium vitamin C salt.

[0100] Among the components of the above-mentioned meal replacement powder, the soluble dietary fiber is selected from at least one of water-soluble soybean dietary fiber, water-soluble brown rice fiber, water-soluble germ rice fiber, water-soluble corn fiber, water-soluble barley fiber, water-soluble rice bran fiber, water-soluble root vegetable fiber, water-soluble kelp fiber, water-soluble carrot fiber, water-soluble four-quarter fiber, water-soluble red bean fiber, water-soluble pea fiber, water-soluble sweet potato fiber and water-soluble kelp fiber.

[0101] Among the components of the above-mentioned meal replacement powder, the food-friendly acceptable auxiliary materials include seasonings, flavoring agents and / or food preservatives.

[0102] Specifically, the formula of the meal replacement powder of the test product involved in this experiment is shown in Table 5.

[0103] Table 5

[0104] Implementation formula Example 1 8 parts of fermented freeze-dried powder, 65 parts of soluble dietary fiber, 0.5 parts of sodium L-glutamate Example 2 8 parts of fermented freeze-dried powder, 65 parts of soluble dietary fiber, 0.5 parts of sodium L-glutamate Example 3 8 parts of fermented freeze-dried powder, 65 parts of soluble dietary fiber, 0.5 parts of sodium L-glutamate Comparative Example 1 8 parts of fermented freeze-dried powder, 65 parts of soluble dietary fiber, 0.5 parts of sodium L-glutamate Comparative Example 2 8 parts of fermented freeze-dried powder, 65 parts of soluble dietary fiber, 0.5 parts of sodium L-glutamate Comparative Example 3 8 parts of fermented freeze-dried powder, 65 parts of soluble dietary fiber, 0.5 parts of sodium L-glutamate Comparative Example 4 8 parts of fermented freeze-dried powder, 65 parts of soluble dietary fiber, 0.5 parts of sodium L-glutamate Comparative Example 5 8 parts of fermented freeze-dried powder, 65 parts of soluble dietary fiber, 0.5 parts of sodium L-glutamate Comparative Example 6 8 parts of fermented freeze-dried powder, 65 parts of soluble dietary fiber, 0.5 parts of sodium L-glutamate Comparative Example 7 8 parts of Panax notoginseng powder, 65 parts of soluble dietary fiber, 0.5 parts of sodium L-glutamate

[0105] 3. Experimental Grouping

[0106] After 1 week of adaptive feeding, the experiment was started, and C57BL / 6J mice were set as the normal control group. KK / Upj-Ay / J diabetic model mice whose blood glucose values ​​reached the diagnostic criteria for diabetes (i.e., ≧11.1mmol / L) were randomly divided into a model group, an intervention group, and a positive group according to random blood glucose levels, with 20 animals in each group, half of which were male and half were female.

[0107] The intervention group was gavaged with the test substances twice daily, with a dosage of 20 mg / kg.bw and a gavage volume of 0.1 mL / 10 g, at intervals of more than 4 hours for 4 consecutive weeks.

[0108] The daily oral administration dose of metformin hydrochloride to the mice in the positive group was: 128 mg / kg.bw in the first week, 204 mg / kg.bw in the second week, 280 mg / kg.bw in the third week, and 303 mg / kg.bw from the fourth week to the end of the experiment, with an oral administration volume of 0.1 mL / 10 g.

[0109] The normal control group and the model group were given an equal volume of 0.5% sodium carboxymethyl cellulose. The temperature of the mouse room was maintained at 20-24°C, with 12 hours of day and night, and a relative humidity of about 60-65%. The experiment lasted for 4 weeks.

[0110] 4. Weight and blood sugar monitoring

[0111] Weigh once a week. Measure random blood sugar and fasting blood sugar once a week during blood sugar administration. Fast for 4 hours before fasting blood sugar measurement. Wipe the tip of the mouse tail with an alcohol cotton ball, and take about 2 μL of blood and drop it on a blood sugar test strip to measure the blood sugar value.

[0112] 5. Four blood lipids, insulin, glycosylated hemoglobin test and tissue pathology test

[0113] After 4 weeks of administration, mice were fasted for 16 hours but not water, and then blood was collected by eyeball removal. After natural coagulation, the blood was centrifuged at 3000 rpm for 10 minutes to separate the serum. Four indicators, total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were detected by biochemical analyzer (AU5800 series, BECKMAN). The insulin content was detected by INS ELISA kit (Cat. No.: JL18382, Jianglai Biology), and the glycated hemoglobin content was detected by ELISA kit (Shanghai Yiyan Biotechnology Co., Ltd.). The insulin sensitivity index (ISI) was calculated. ISI is the reciprocal of the product of fasting blood glucose value and fasting blood insulin value, which is non-normally distributed, and its natural logarithm value was taken for analysis.

[0114] Epididymal fat of testicular appendages of mice in each group was taken in an appropriate size and fixed in a bottle of fat fixative. A square block of 1 cm in size from the middle of the largest lobe of the liver was taken and fixed in a bottle of neutral formaldehyde fixative for 24 hours. Paraffin sections were made and stained with hematoxylin before observation under an optical fiber microscope.

[0115] Data analysis: All test data were expressed as mean and standard deviation. SPSS13.0 software was used to process the data, and multiple comparisons and significant differences were performed on each column of data.

[0116] 6. Effects on the intestinal flora of mice

[0117] (1) The feces of mice in each group were collected, and genomic DNA was extracted from the samples using the CTAB method. DNA amplification was then performed using primers F:cctaygggrbgcascag; R:ggactacnngggtatctaat. The amplified products were detected by agarose gel electrophoresis, and the target bands were recovered. The mixed PCR products were purified using the genejetmgel extraction kit (Thermo Scientific). The library was constructed using the Ion Plus Fragment Library Kit 48rxns from Thermofisher Company, and after Qubit quantification and library detection, the library was sequenced using the IonSSTMXL from Thermofisher Company.

[0118] (2) Data Analysis

[0119] First, Cutadapt (V1.9.1, http: / / cutadapt.readthedocs.io / en / stab / ) was applied to cut the low-quality part of the reads, and the data of each sample was split according to the Barcode. The raw data obtained by the preliminary quality control was intercepted (Raw reads, after the above processing, the reads also need to be removed from the chimera sequence. The sequence was compared with the species annotation database through (https: / / github.com / torognes / vsearch / ) to remove the chimera sequence, and finally the final valid data (Clean Reads) was obtained.

[0120] Uparse software (Uparse v7.0.1001, http: / / www.drive5.com / uparse / ) was used to cluster the Clean Reads of all samples. The identity of 97% was set as the default value. The sequences were clustered into OTUs (Operational Taxonomic Units). At the same time, representative sequences of OTUs were selected. According to the algorithm principle, the representative sequences of OTUs were the sequences with the highest frequency of occurrence. The Mothur method was used with the SILVA132 (http: / / www.arb-silva.de / ) The OTUs sequences were annotated with the SSU rRNA database (the threshold was set to 0.8-1). After obtaining the taxonomic information, the community composition of each sample was statistically analyzed as follows: kingdom, phylum, class, order, family, genus, and species. Rapid multiple sequence alignment was performed using MUSCLE (Version 3.8.31, http: / / www.drives.com / muscle / ). Finally, the data of each group of samples were homogenized based on the sample with the least amount of data.

[0121] Qiime software (Version 1.9.1) was used to calculate observed-species, Chaol, R software (Version 2.15.3) was used for analysis, and diversity analysis was used to evaluate the complexity of species differences among samples.

[0122] 2. Results

[0123] Table 6

[0124]

[0125] As shown in Table 6, the body weight and random blood glucose of the model group mice increased significantly after the 4th week of the experiment, while the random blood glucose of the positive control group mice was significantly lower than that of the model group, but it did not significantly reduce the body weight, indicating that it did not have a weight loss effect on the model mice. In the intervention group, the body weight and random blood glucose of the KK / Upj-Ay / J diabetic model mice were significantly lower than those of the model group and the positive control group mice after the 4th week of intervention of the meal replacement powder provided in Examples 1 to 3, and were not much different from those of the normal group mice, which shows that the meal replacement powder prepared based on the fermented freeze-dried powder of Panax notoginseng fermented by probiotics in the present application example has hypoglycemic and weight loss effects for KK / Upj-Ay / J diabetic model mice.

[0126] Table 7

[0127]

[0128] As shown in Table 7, the four blood lipids of the model group mice increased significantly after the fourth week of the experiment, while the random blood glucose of the positive control group mice was significantly lower than that of the model group, but still significantly higher than that of the normal group, indicating that the positive drug has limited lipid-lowering effect on the model mice. In the intervention group, the meal replacement powder provided in Examples 1 to 3 intervened in the KK / Upj-Ay / J diabetic model mice for the fourth week, and the four blood lipids were significantly lower than those of the model group and the positive control group mice, and were not much different from the normal group mice, which shows that the meal replacement powder prepared based on the fermented freeze-dried powder of Panax notoginseng fermented by probiotics in the present application example has lipid-lowering effect on KK / Upj-Ay / J diabetic model mice.

[0129] Furthermore, the organ index and fat index of mice were tested to comprehensively reflect the effect of drug intervention on the health status and body fat content of mice. The results are shown in Table 8.

[0130] Table 8

[0131]

[0132] As shown in Table 8, the BMI index, Lee's index, white fat index and liver index of the mice in the model group were significantly higher than those in the normal group, indicating that the mice in the model group not only had symptoms of hyperglycemia, hyperlipidemia and obesity, but also had the possibility of liver damage. In the intervention group, after the meal replacement powder provided in Examples 1 to 3 was used to intervene in the mice, their BMI index, Lee's index, white fat index and liver index were significantly reduced, especially the white fat index, which shows that the meal replacement powder provided in the examples of the present application not only has the effects of lowering blood sugar and lipids, and losing weight, but also has less damage to the organs of mice.

[0133] In addition, if Figure 2 As shown, the fat of normal mice is arranged in an orderly manner and has a regular shape, while the fat cells of the model group are arranged in a disorderly manner, of different sizes, and the fat cells are swollen. Due to the abnormal accumulation of fat, the size of the fat cells can reflect the degree of obesity in the body. Figure 3 The average size of fat cells in the model group was significantly higher than that in the normal group; Figure 4 , 5 In the experiment, both the intervention group (Example 1) and the positive control group significantly reduced the size of mouse fat cells, indicating that the meal replacement powder provided in the example has a good weight loss effect.

[0134] Since the meal replacement powder provided in the examples of the present application is prepared based on the freeze-dried powder of the fermentation broth of Panax notoginseng fermented with probiotics, this experiment further investigated its effect on the richness of each bacterial genera that make up the intestinal flora of each group of mice. The results are shown in Tables 9 and 10.

[0135] Table 9 Relative Abundance

[0136]

[0137] Table 10 Relative Abundance

[0138]

[0139]

[0140] As shown in Tables 9 and 10, the intestinal flora is mainly composed of Bacteroidetes (Bac.) and Firmicutes (Fir.), followed by Actinobacteria (Ac.), Deferribacterium (Def.), Tle., Proteobacteria (Pro.), etc. Among them, Firmicutes mainly include Lactobacillus (Lac.), Bifidobacterium (Bif.), Blautia (Bla.), Marvinbryantia (Mar.) and S. inulinus added to meal replacement powder, which are all probiotics.

[0141] Moreover, relative to the normal group, the abundance of Firmicutes in the intestinal flora of the model group mice decreased, especially the Bifidobacterium and Blautia genera, and the undefined bacteria (undentified Bacteria) and Proteobacteria (often pathogenic bacteria) in their intestinal flora increased significantly, indicating that the intestinal microecology of the model group mice was pathologically affected, which was not conducive to their physiological health. After the intervention of the meal replacement powder provided in Examples 1 to 3 of the present application, the abundance of Firmicutes in the mouse flora increased significantly, and after supplementing with Lactobacillus inulinus, its intestinal flora showed a certain abundance, and although Comparative Example 5 was confirmed to have a certain hypoglycemic and lipid-lowering effect by the aforementioned experiments, the intestinal abundance of Lactobacillus inulinus was far less than that of Examples 1 to 3, which shows that the fermentation medium used in the fermentation process of Lactobacillus inulinus in Comparative Example 5 has a significant effect on the number of viable bacteria in the obtained fermentation freeze-dried powder and the final effect on the abundance of the mouse intestine. However, after the other control groups intervened in mice, the increase in the abundance of Firmicutes was not obvious, which was not conducive to the transformation of the intestinal microecology of mice towards a probiotic direction.

[0142] The above is only a preferred specific implementation of the present application, but the protection scope of the present application is not limited thereto. Any changes or substitutions that can be easily conceived by any technician familiar with the technical field within the technical scope disclosed in the present application should be covered within the protection scope of the present application.

Claims

1. A freeze-dried powder of a Panax notoginseng active ingredient composition, wherein the Panax notoginseng is the dried rhizome of Polygonum chinense, a plant of the genus Polygonum in the family Polygonaceae, characterized in that: It is prepared by the following preparation method: preparing a working seed solution containing live Lactobacillus inulinus sporobacterium, wherein the working seed solution is obtained by inoculating activated Lactobacillus inulinus sporobacterium onto an acclimation medium for acclimation culture; preparing a seed solution, wherein the seed solution is inoculated into a seed culture medium by the working seed solution, and cultured at 37° C. for 18 hours to obtain the seed solution; the seed culture medium comprises 3 g / L Jerusalem artichoke whole powder, 12 g / L Panax notoginseng powder, 5 g / L corn flour and 7 g / L buckwheat flour; preparing a fermentation liquid, wherein the fermentation liquid is inoculated into a fermentation medium and cultured to obtain the fermentation liquid; the fermentation medium comprises 5 g / L Jerusalem artichoke powder, 15 g / L Panax notoginseng powder, 8 g / L corn powder and 10 g / L buckwheat powder; and The fermentation liquid is concentrated and dried to obtain the Panax notoginseng active composition; the Panax notoginseng active composition has an α-glucosidase inhibition rate of not less than 51.49% and an OARC value of not less than 32.60 μmol TE / mL; The active ingredient of Panax notoginseng comprises, by weight per thousand, 11.93-14.61 wt‰ resveratrol, 17.41-20.69 wt‰ phlorizin, 9.18-11.08 wt‰ quercetin, 1.87-2.75 wt‰ 6-methoxy-7-hydroxycoumarin, 4.108-4.212 wt‰ catechin, 1.732-1.788 wt‰ southern candelilla resin phenol, 0.745-0.775 wt‰ protocatechuic acid methyl ester, 0.317-0.363 wt‰ methyl gallate, 0.449-0.491 wt‰ ‰ n-butyl gallate, 0.546-0.574wt‰ 6-O-(E)-caffeoyl glucoside, 1.426-1.534wt‰ carotene, 16.93-19.39wt‰ benzoyl β-D-pyranoglucoside, 2.89-3.61wt‰ 2,8-triol-1-O-β-D-pyranoglucoside, 2.732-2.848wt‰ quercetin-3-O-α-D-arabinofuranoside and 13.56-17.14wt‰ ferulic acid, and not less than 100 million / g of live bacterial powder of Lactobacillus inulinus; Wherein, the acclimation culture includes acclimation culture carried out in a first acclimation culture medium, a second acclimation culture medium and a third acclimation culture medium in sequence, the first acclimation culture medium contains 18.0 g / L Jerusalem artichoke whole powder and 2.0 g / L Panax notoginseng powder, the second acclimation culture medium contains 10.0 g / L Jerusalem artichoke whole powder and 10.0 g / L Panax notoginseng powder, and the third acclimation culture medium contains 8.0 g / L Jerusalem artichoke whole powder and 12.0 g / L Panax notoginseng powder.

2. A composition comprising 0.0001 to 10 parts of the Panax notoginseng active composition according to claim 1, 50 to 80 parts of soluble dietary fiber, and other food-acceptable auxiliary materials.

3. Use of the composition according to claim 2 in preparing products related to weight loss and lipid reduction.

4. Use of the composition according to claim 2 in preparing hypoglycemic related products.

5. Use of the composition according to claim 2 in the preparation of products that are beneficial to the transformation of intestinal microecology towards a probiotic direction.

6. A fermentation liquid of a Panax notoginseng active composition, wherein the Panax notoginseng is the dried rhizome of Polygonum chinense, a plant of the genus Polygonum of the family Polygonaceae, characterized in that: It is prepared by the following preparation method: preparing a working seed solution containing live Lactobacillus inulinus sporobacterium, wherein the working seed solution is obtained by inoculating activated Lactobacillus inulinus sporobacterium onto an acclimation medium for acclimation culture; preparing a seed solution, wherein the seed solution is inoculated into a seed culture medium by the working seed solution, and cultured at 37° C. for 18 hours to obtain the seed solution; the seed culture medium comprises 3 g / L Jerusalem artichoke whole powder, 12 g / L Panax notoginseng powder, 5 g / L corn flour and 7 g / L buckwheat flour; preparing a fermentation liquid, wherein the fermentation liquid is inoculated into a fermentation medium by the seed liquid to obtain the fermentation liquid; the fermentation medium comprises 5 g / L Jerusalem artichoke powder, 15 g / L Panax notoginseng powder, 8 g / L corn powder and 10 g / L buckwheat powder; The active ingredient of Panax notoginseng comprises, by weight per thousand, 11.93-14.61 wt‰ resveratrol, 17.41-20.69 wt‰ phlorizin, 9.18-11.08 wt‰ quercetin, 1.87-2.75 wt‰ 6-methoxy-7-hydroxycoumarin, 4.108-4.212 wt‰ catechin, 1.732-1.788 wt‰ southern candelilla resin phenol, 0.745-0.775 wt‰ protocatechuic acid methyl ester, 0.317-0.363 wt‰ methyl gallate, 0.449-0.491 wt‰ ‰ n-butyl gallate, 0.546-0.574wt‰ 6-O-(E)-caffeoyl glucoside, 1.426-1.534wt‰ carotene, 16.93-19.39wt‰ benzoyl β-D-pyranoglucoside, 2.89-3.61wt‰ 2,8-triol-1-O-β-D-pyranoglucoside, 2.732-2.848wt‰ quercetin-3-O-α-D-arabinofuranoside and 13.56-17.14wt‰ ferulic acid, and not less than 100 million / g of live bacterial powder of Lactobacillus inulinus; Wherein, the acclimation culture includes acclimation culture carried out in a first acclimation culture medium, a second acclimation culture medium and a third acclimation culture medium in sequence, the first acclimation culture medium contains 18.0 g / L Jerusalem artichoke whole powder and 2.0 g / L Panax notoginseng powder, the second acclimation culture medium contains 10.0 g / L Jerusalem artichoke whole powder and 10.0 g / L Panax notoginseng powder, and the third acclimation culture medium contains 8.0 g / L Jerusalem artichoke whole powder and 12.0 g / L Panax notoginseng powder.

7. A medicine comprising the composition according to claim 2.

Images